Patents by Inventor Klaus Klumpp

Klaus Klumpp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS
    Publication number: 20220362266
    Abstract: The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: April 10, 2020
    Publication date: November 17, 2022
    Inventors: Ronald Hawley, Klaus Klumpp
  • 4?-fluoro-2?-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 11351186
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: June 7, 2022
    Assignee: RIBOSCIENCE LLC
    Inventors: Mark Smith, Klaus Klumpp
  • QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS
    Publication number: 20220056052
    Abstract: The present disclosure provides certain quinazoline compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: December 27, 2019
    Publication date: February 24, 2022
    Inventors: Ronald HAWLEY, Klaus KLUMPP
  • Combinations and methods comprising a capsid assembly inhibitor
    Patent number: 11129834
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: September 28, 2021
    Assignees: Novira Therapeutics, Inc., Janssen Sciences Ireland Unlimited Company
    Inventors: George Hartman, Osvaldo Flores, Klaus Klumpp, Man Iu Lam, Jan Martin Berke
  • 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20210046100
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Application
    Filed: May 4, 2020
    Publication date: February 18, 2021
    Inventors: Mark SMITH, Klaus KLUMPP
  • COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR
    Publication number: 20190365767
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Application
    Filed: August 15, 2019
    Publication date: December 5, 2019
    Inventors: George Hartman, Osvaldo Flores, Klaus Klumpp, Man Iu Lam, Jan Martin Berke
  • Combinations and methods comprising a capsid assembly inhibitor
    Patent number: 10441589
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: October 15, 2019
    Assignees: NOVIRA THERAPEUTICS, INC., Janssen Sciences Ireland Unlimited Company
    Inventors: George Hartman, Osvaldo Flores, Klaus Klumpp, Man Iu Lam, Jan Martin Berke
  • COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR
    Publication number: 20170340642
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Application
    Filed: April 14, 2017
    Publication date: November 30, 2017
    Inventors: George HARTMAN, Osvaldo FLORES, Klaus KLUMPP, Man Iu LAM, Jan Martin BERKE
  • Antiviral phosphoramidates
    Patent number: 7608599
    Abstract: The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: October 27, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Klaus Klumpp, Joseph Armstrong Martin, Christopher McGuigan, David Bernard Smith
  • Antiviral phosphoramidates
    Publication number: 20070042988
    Abstract: The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases.
    Type: Application
    Filed: August 11, 2006
    Publication date: February 22, 2007
    Inventors: Klaus Klumpp, Joseph Martin, Christopher McGuigan, David Smith